DNAzymes Dz13 target the c-jun possess antiviral activity against influenza A viruses

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Emerging drug-resistant influenza A virus strains necessitate novel therapeutic strategies.
• c-jun, a downstream molecule of JNK, plays a role in viral infections and inflammatory responses.
• Targeting c-jun presents a potential therapeutic avenue for influenza treatment.

Purpose of the Study:

• To investigate the efficacy of DNAzymes targeting c-jun (Dz13) in a mouse model of influenza A virus infection.
• To assess the safety and therapeutic potential of Dz13 against influenza A virus.

Main Methods:

• Administration of DNAzymes Dz13 to influenza A virus-infected BALB/c mice.
• Evaluation of Dz13 toxicity in A549 cells and mice.
• Assessment of survival rates, pulmonary inflammatory responses, viral load, and T cell proliferation in treated mice.

Main Results:

• Dz13 demonstrated no significant toxicity in cell cultures or in vivo.
• Dz13 treatment significantly enhanced survival rates in infected mice.
• Dz13 reduced pulmonary inflammation and viral burden.
• Dz13 treatment led to impaired proliferation of infection-induced CD4+ and CD8+ T cells.

Conclusions:

• DNAzymes targeting c-jun (Dz13) are effective in reducing influenza A virus replication and associated inflammation in vivo.
• Dz13 exhibits a favorable safety profile.
• Dz13 represents a promising therapeutic candidate for treating influenza A viral infections.